- Zivo Bioscience board moved to delist common stock and warrants from OTC Markets.
- Decision cited costs and administrative burden of maintaining public reporting.
- Next step targets Form 15 filing on or around March 30, 2026.
- Filing is expected to end periodic filings immediately, including Forms 10-K and 10-Q.
- Management plans to redirect resources toward animal health and nutrition operations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-002928), on March 30, 2026, and is solely responsible for the information contained therein.
Comments